Literature DB >> 20816614

Limitations of a contemporary prostate biopsy: the blind march forward.

John T Wei1.   

Abstract

In an attempt to reduce morbidity, focal targeted therapies and active surveillance have become increasingly popular treatment choices for localized prostate cancer. However, these modalities rely heavily on accurate and reliable tumor localization information provided by a prostate biopsy. Evidence that our contemporary biopsy techniques can do little more than detect some prostate cancers is notably lacking. What is meant by the accuracy and reliability of a prostate biopsy and why they are such important concepts to focal therapy and active surveillance are discussed. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20816614      PMCID: PMC2936919          DOI: 10.1016/j.urolonc.2009.12.022

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  29 in total

Review 1.  Is it time to consider a role for MRI before prostate biopsy?

Authors:  Hashim U Ahmed; Alex Kirkham; Manit Arya; Rowland Illing; Alex Freeman; Clare Allen; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

Review 2.  Photodynamic therapy for prostate cancer--a review of current status and future promise.

Authors:  Caroline M Moore; Doug Pendse; Mark Emberton
Journal:  Nat Clin Pract Urol       Date:  2009-01

Review 3.  Best practice statement on cryosurgery for the treatment of localized prostate cancer.

Authors:  Richard J Babaian; Bryan Donnelly; Duke Bahn; John G Baust; Martin Dineen; David Ellis; Aaron Katz; Louis Pisters; Daniel Rukstalis; Katsuto Shinohara; J Brantley Thrasher
Journal:  J Urol       Date:  2008-09-25       Impact factor: 7.450

4.  Quality of life and satisfaction with outcome among prostate-cancer survivors.

Authors:  Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

5.  Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer.

Authors:  Ifeanyichukwu I Megwalu; Genoa G Ferguson; John T Wei; Vladimir Mouraviev; Thomas J Polascik; Samir Taneja; Linda Black; Gerald L Andriole; Adam S Kibel
Journal:  BJU Int       Date:  2008-08-05       Impact factor: 5.588

6.  Comparison of cancers detected at only a sextant or alternative location.

Authors:  Atsushi Ochiai; Patricia Troncoso; Richard J Babaian
Journal:  BJU Int       Date:  2007-12-05       Impact factor: 5.588

7.  Outcomes of localized prostate cancer following conservative management.

Authors:  Grace L Lu-Yao; Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Michael J Barry; Anthony Zietman; Michael O'Leary; Elizabeth Walker-Corkery; Siu-Long Yao
Journal:  JAMA       Date:  2009-09-16       Impact factor: 56.272

8.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Authors:  Juan-Miguel Mosquera; Rohit Mehra; Meredith M Regan; Sven Perner; Elizabeth M Genega; Gerri Bueti; Rajal B Shah; Sandra Gaston; Scott A Tomlins; John T Wei; Michael C Kearney; Laura A Johnson; Jeffrey M Tang; Arul M Chinnaiyan; Mark A Rubin; Martin G Sanda
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

9.  Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy.

Authors:  Gary Onik; Winston Barzell
Journal:  Urol Oncol       Date:  2008 Sep-Oct       Impact factor: 3.498

10.  Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations after radical prostatectomy.

Authors:  Ryan T Schulte; David P Wood; Stephanie Daignault; Rajal B Shah; John T Wei
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

View more
  5 in total

1.  Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.

Authors:  J J Tosoian; R Alam; C Gergis; A Narang; N Radwan; S Robertson; T McNutt; A E Ross; D Y Song; T L DeWeese; P T Tran; P C Walsh
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-03       Impact factor: 5.554

2.  Molecular heterogeneity of localized prostate cancer: more different than alike.

Authors:  Jeffrey J Tosoian; Emmanuel S Antonarakis
Journal:  Transl Cancer Res       Date:  2017-02       Impact factor: 1.241

Review 3.  A biomedical engineering approach to mitigate the errors of prostate biopsy.

Authors:  Hashim Uddin Ahmed; Mark Emberton; Gordon Kepner; Jeremy Kepner
Journal:  Nat Rev Urol       Date:  2012-02-07       Impact factor: 14.432

Review 4.  Diagnosis and Monitoring of Prostatic Lesions: A Comparison of Three Modalities: Multiparametric MRI, Fusion MRI/Transrectal Ultrasound (TRUS), and Traditional TRUS.

Authors:  Antoinette Birs; Peter H Joyce; Zoran J Pavlovic; Alexander Lim
Journal:  Cureus       Date:  2016-07-18

5.  Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study.

Authors:  Nicola L Robertson; Yipeng Hu; Hashim U Ahmed; Alex Freeman; Dean Barratt; Mark Emberton
Journal:  Eur Urol       Date:  2013-01-03       Impact factor: 20.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.